1upHealth
Boston, MA | www.1up.health
1upHealth helps payers, providers, and digital health companies build an end-to-end FHIR data strategy that is enabled by best-in-class tools on a scalable, serverless, and secure platform.
Our team of seasoned healthcare investors provides strategic and often non-dilutive capital tailored to healthcare and pharma business timelines, whether to develop or launch new medicines, acquire assets, or provide growth capital to finance strategic initiatives.
We are passionate about forming long-term partnerships with companies creating new technologies to address our most pressing healthcare challenges and improve patient care. Our experienced life sciences and technology teams focus on collaborating to develop AI and software-related themes within the healthcare space.
We invest across the sector and have partnered with companies in drug development and marketing, devices and diagnostics, generics, pharma and healthcare business services, and contract research, development and manufacturing.
Healthcare IT and Software
Healthcare Data and AI
OTC, Consumer, Cosmeceuticals
Pharma Services, CROs, CDMOs, Life Science Tools
Medical Devices
Diagnostics
Pharmaceuticals and Biotechnology
Consumer Services
HEALTHCARE and LIFE SCIENCES
SELECT INVESTMENTS
Beginning in 2020, Sixth Street provided $750 million in non-dilutive financing to support the commercial launch of or Nurtec® ODT, the first FDA-approved oral medicine for the prevention and treatment of migraines. On May 10, 2022, Pfizer announced its acquisition of Biohaven for $11.6 billion.
SELECT INVESTMENTS
Sixth Street led a combined $1.25 billion strategic financing for Blueprint Medicine, a biopharmaceutical company with a proven track record of success in developing and commercializing precision therapies to broad patient populations through internal R&D and strategic business development.
SELECT INVESTMENTS
In 2021, Sixth Street made a strategic investment in Datavant, a leading healthcare data platform dedicated to helping protect, match, and share health data.
SELECT INVESTMENTS
Since first investing in 2018, Sixth Street has invested over $450 million of growth capital in Caris Life Sciences, a leading innovator in molecular science and technology developing the next generation of precision oncology profiling.
SELECT INVESTMENTS
In 2020, Sixth Street invested in MDLIVE, one of the fastest growing telehealth providers of online and on-demand healthcare delivery services and software platforms in the United States. MDLIVE was acquired by Cigna’s Evernorth in 2021.
Reproduced with permission from Bloomberg L.P.
We welcomed Jennifer Doudna, Ph.D., Nobel laureate and co-discoverer of CRISPR, as our Chief Science Advisor in February 2022. Dr. Doudna assists Sixth Street in our long-term efforts to identify, evaluate, and advance commercial development opportunities within the CRISPR and gene-editing ecosystem. She is also leading the build of our Scientific Advisory Board, which will advise our team as we continue to finance the development and commercialization of innovative therapeutics and invest in healthcare technology companies across all stages of growth.
Learn MoreSIXTH STREET
*AUM is presented as of 6/1/2025, unless otherwise noted. AUM includes the net asset value, plus outstanding leverage and asset-based financing undrawn amounts, in respect of private investment funds, certain co-investment vehicles and accounts for which Sixth Street provides investment management or advisory services, as well as capital that such funds, vehicles and accounts have the right to call from investors pursuant to the terms of their capital commitments as of 3/31/2025 and additional fundraising commitments and fund, vehicle and account liquidations through 6/1/2025. In the case of Sixth Street-managed business development companies, AUM reflects their total assets (i.e., gross of any fund-level liabilities) plus asset-based financing undrawn amounts, as well as capital that such companies have the right to call from investors pursuant to the terms of their capital commitments. With respect to Sixth Street-managed collateralized loan obligations, AUM reflects the face amount of debt and equity outstanding. AUM includes capital to be managed in connection with the strategic partnership discussed in the Sixth Street press release that can be accessed here. Calculation of AUM differs from the calculation of regulatory assets under management in Form ADV filings and may differ from the AUM calculation methodologies used by other investment managers.